Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (10321) 10321
Publication (978) 978
Book Review (172) 172
Book Chapter (85) 85
Newspaper Article (52) 52
Dissertation (22) 22
Conference Proceeding (21) 21
Magazine Article (12) 12
Book / eBook (11) 11
Web Resource (8) 8
Trade Publication Article (5) 5
Paper (3) 3
Data Set (2) 2
Journal / eJournal (1) 1
Newsletter (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (5724) 5724
humans (5174) 5174
microbiology (3075) 3075
infectious diseases (2608) 2608
anti-bacterial agents - pharmacology (2313) 2313
bacteria (2200) 2200
antibiotics (2113) 2113
microbial sensitivity tests (2067) 2067
resistant staphylococcus-aureus (1991) 1991
pharmacology & pharmacy (1957) 1957
pseudomonas-aeruginosa (1758) 1758
male (1597) 1597
female (1576) 1576
anti-bacterial agents - therapeutic use (1560) 1560
drug resistance (1551) 1551
infections (1483) 1483
drug resistance in microorganisms (1458) 1458
animals (1293) 1293
health aspects (1230) 1230
escherichia-coli (1168) 1168
pseudomonas aeruginosa (1112) 1112
middle aged (1062) 1062
staphylococcus aureus (1006) 1006
research (969) 969
aged (962) 962
analysis (959) 959
adult (953) 953
methicillin-resistant staphylococcus aureus - drug effects (953) 953
epidemiology (915) 915
antimicrobial agents (912) 912
infection (877) 877
staphylococcus-aureus (864) 864
pseudomonas aeruginosa - drug effects (861) 861
nosocomial infections (856) 856
risk factors (846) 846
gram-negative bacteria (844) 844
pneumonia (826) 826
drug resistance, bacterial (815) 815
antibacterial agents (808) 808
pathogens (804) 804
antimicrobial resistance (801) 801
methicillin-resistant staphylococcus aureus (789) 789
drug resistance, multiple, bacterial (784) 784
mortality (716) 716
risk-factors (711) 711
staphylococcus infections (694) 694
immunology (679) 679
hospitals (675) 675
resistant (670) 670
medicine (630) 630
antibiotic resistance (619) 619
retrospective studies (618) 618
methicillin-resistant (616) 616
antibacterial activity (612) 612
infectious disease (597) 597
biotechnology & applied microbiology (587) 587
research article (580) 580
in-vitro (578) 578
bacteria - drug effects (576) 576
ventilator-associated pneumonia (572) 572
cross infection - microbiology (570) 570
care and treatment (565) 565
treatment outcome (561) 561
gram-negative bacteria - drug effects (560) 560
klebsiella-pneumoniae (553) 553
antimicrobial activity (549) 549
multidrug-resistant (544) 544
bacterial infections (541) 541
anti-bacterial agents - administration & dosage (540) 540
mrsa (536) 536
biochemistry & molecular biology (525) 525
staphylococcus aureus - drug effects (522) 522
biochemical phenomena, metabolism, and nutrition (516) 516
staphylococcus aureus infections (515) 515
biofilms (511) 511
anti-bacterial agents - chemistry (506) 506
antibiotic-resistance (501) 501
prevalence (497) 497
acinetobacter-baumannii (496) 496
internal medicine (483) 483
aged, 80 and over (478) 478
therapy (473) 473
resistance (466) 466
surgery (463) 463
bacterial infections - drug therapy (460) 460
bacterial pneumonia (460) 460
colistin (459) 459
staphylococcal infections - microbiology (459) 459
chemistry, medicinal (442) 442
methicillin-resistant staphylococcus aureus - isolation & purification (440) 440
adolescent (432) 432
vancomycin (432) 432
susceptibility (425) 425
cross infection (424) 424
e coli (424) 424
intensive-care-unit (416) 416
mice (415) 415
staphylococcal infections - drug therapy (415) 415
article (414) 414
medicine & public health (408) 408
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9955) 9955
French (272) 272
Japanese (74) 74
Spanish (64) 64
German (51) 51
Chinese (22) 22
Korean (21) 21
Portuguese (13) 13
Polish (9) 9
Russian (6) 6
Turkish (5) 5
Italian (4) 4
Arabic (3) 3
Persian (3) 3
Slovenian (2) 2
Czech (1) 1
Hungarian (1) 1
Icelandic (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection
by Clancy, J P and Dupont, L and Konstan, M W and Billings, J and Fustik, S and Goss, C H and Lymp, J and Minic, P and Quittner, A L and Rubenstein, R C and Young, K R and Saiman, L and Burns, J L and Govan, J R W and Ramsey, B and Gupta, R and Arikace Study Grp and Arikace Study Group
Thorax, ISSN 0040-6376, 09/2013, Volume 68, Issue 9, pp. 818 - 825
Rationale Arikace is a liposomal amikacin preparation for aerosol delivery with potent Pseudomonas aeruginosa killing and prolonged lung deposition. Objectives... 
INHALED AZTREONAM LYSINE | LUNG | Cystic Fibrosis | EFFICACY | Bacterial Infection | AIRWAY PSEUDOMONAS | ELIMINATION | RESISTANT STAPHYLOCOCCUS-AUREUS | IDENTIFICATION | LIPOSOMAL AMIKACIN | Respiratory Infection | TOBRAMYCIN | RESPIRATORY SYSTEM | CYSTIC-FIBROSIS GENE | Sputum - microbiology | Double-Blind Method | Pseudomonas Infections - drug therapy | Cystic Fibrosis - physiopathology | Humans | Male | Cystic Fibrosis - complications | Forced Expiratory Volume | Microbial Sensitivity Tests | Young Adult | Amikacin - adverse effects | Amikacin - administration & dosage | Analysis of Variance | Adolescent | Quality of Life | Adult | Female | Pseudomonas aeruginosa | Anti-Bacterial Agents - adverse effects | Liposomes | Anti-Bacterial Agents - administration & dosage | Child | Nebulizers and Vaporizers | Amikacin | Causes of | Cystic fibrosis | Dosage and administration | Drug therapy | Risk factors | 1506
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa
by Munita, Jose M and Aitken, Samuel L and Miller, William R and Perez, Federico and Rosa, Rossana and Shimose, Luis A and Lichtenberger, Paola N and Abbo, Lilian M and Jain, Rupali and Nigo, Masayuki and Wanger, Audrey and Araos, Rafael and Tran, Truc T and Adachi, Javier and Rakita, Robert and Shelburne, Samuel and Bonomo, Robert A and Arias, Cesar A
Clinical Infectious Diseases, ISSN 1058-4838, 07/2017, Volume 65, Issue 1, pp. 158 - 161
A multicenter, retrospective study of patients infected with carbapenem-resistant Pseudomonas aeruginosa who were treated with ceftolozane/tazobactam was... 
Ceftolozane | multidrug resistant | carbapenem resistant | P. aeruginosa | INFECTIOUS DISEASES | THERAPY | COLISTIN | HOSPITALS | MICROBIOLOGY | ceftolozane | IMMUNOLOGY | TAZOBACTAM | IN-VITRO ACTIVITY | Pseudomonas Infections - drug therapy | Humans | Middle Aged | Male | Pseudomonas aeruginosa - drug effects | Pseudomonas Infections - microbiology | Cephalosporins - therapeutic use | Anti-Bacterial Agents - therapeutic use | Carbapenems - pharmacology | Pseudomonas Infections - epidemiology | Penicillanic Acid - therapeutic use | Adult | Female | Aged | Anti-Bacterial Agents - adverse effects | Anti-Bacterial Agents - pharmacology | Retrospective Studies | Penicillanic Acid - adverse effects | Penicillanic Acid - analogs & derivatives | Cephalosporins - adverse effects | Causes of | Klebsiella infections | Pseudomonas aeruginosa | Care and treatment | Usage | Tazobactam | Brief Reports
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Synergistic Interaction Between Phage Therapy and Antibiotics Clears Pseudomonas Aeruginosa Infection in Endocarditis and Reduces Virulence
by Oechslin, Frank and Piccardi, Philippe and Mancini, Stefano and Gabard, Jérôme and Moreillon, Philippe and Entenza, José M and Resch, Gregory and Que, Yok-Ai
The Journal of Infectious Diseases, ISSN 0022-1899, 03/2017, Volume 215, Issue 5, pp. 703 - 712
Abstract Background. Increasing antibiotic resistance warrants therapeutic alternatives. Here we investigated the efficacy of bacteriophage-therapy (phage)... 
Resistance | Pseudomonas aeruginosa | Antibiotic | Bacteriophage | Phage therapy | Endocarditis | antibiotic | INFECTIOUS DISEASES | EFFICACY | BACTERIOPHAGE THERAPY | ESCHERICHIA-COLI | AMIKACIN | MICROBIOLOGY | IMMUNOLOGY | bacteriophage | resistance | CEFTAZIDIME | RESISTANT | IN-VITRO | GENE | phage therapy | endocarditis | CIPROFLOXACIN | STAIN | Rats, Wistar | Endocarditis - therapy | Virulence | Pseudomonas Infections - therapy | Ciprofloxacin - pharmacology | Rats | Pseudomonas aeruginosa - drug effects | Microbial Sensitivity Tests | Animals | Endocarditis - microbiology | Pseudomonas aeruginosa - pathogenicity | Drug Resistance, Multiple, Bacterial | Female | Anti-Bacterial Agents - pharmacology | Phage Therapy - methods | Pseudomonas aeruginosa infections | Usage | Drug therapy | Risk factors | Major
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Interactions of Methicillin Resistant Staphylococcus aureus USA300 and Pseudomonas aeruginosa in Polymicrobial Wound Infection
by Pastar, Irena and Nusbaum, Aron G and Gil, Joel and Patel, Shailee B and Chen, Juan and Valdes, Jose and Stojadinovic, Olivera and Plano, Lisa R and Tomic-Canic, Marjana and Davis, Stephen C
PLoS ONE, ISSN 1932-6203, 02/2013, Volume 8, Issue 2, p. e56846
Understanding the pathology resulting from Staphylococcus aureus and Pseudomonas aeruginosa polymicrobial wound infections is of great importance due to their... 
SOFT-TISSUE INFECTIONS | PANTON-VALENTINE LEUKOCIDIN | BACTERIAL DIVERSITY | MULTIDISCIPLINARY SCIENCES | IN-VIVO | MOUSE MODEL | BIOFILMS | PRESSURE ULCERS | COLONIZATION | SKIN | VIRULENCE | Immunohistochemistry | Virulence Factors - genetics | Biofilms - growth & development | Methicillin-Resistant Staphylococcus aureus - pathogenicity | Animals | Pseudomonas aeruginosa - pathogenicity | Swine | Wound Infection - microbiology | Wound Infection - metabolism | Female | Virulence Factors - metabolism | Real-Time Polymerase Chain Reaction | Staphylococcal Infections - metabolism | Infection | Drug resistance in microorganisms | Bacterial infections | Analysis | Staphylococcus aureus infections | Pseudomonas aeruginosa | Health aspects | Staphylococcus aureus | Pediatrics | Virulence | Infections | Drug resistance | Methicillin | Synergistic effects | Virulence factors | Surgery | Bacteria | Species | Pathogens | Wound infection | Wound healing | Dermatology | Staphylococcus infections | Antimicrobial agents | Keratinocyte growth factor | Morbidity | Medicine | Biofilms | Healing | Skin | Leukocidin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: Impact of multidrug resistance
by Micek, Scott T and Wunderink, Richard G and Kollef, Marin H and Chen, Catherine and Rello, Jordi and Chastre, Jean and Antonelli, Massimo and Welte, Tobias and Clair, Bernard and Ostermann, Helmut and Calbo, Esther and Torres, Antoni and Menichetti, Francesco and Schramm, Garrett E and Menon, Vandana
Critical Care, ISSN 1364-8535, 05/2015, Volume 19, Issue 1, p. 219
Introduction: Pseudomonas aeruginosa nosocomial pneumonia (Pa-NP) is associated with considerable morbidity, prolonged hospitalization, increased costs, and... 
HOSPITALIZED-PATIENTS | INFECTIONS | RISK-FACTORS | VENTILATOR-ASSOCIATED PNEUMONIA | ACQUIRED PNEUMONIA | CARE-ASSOCIATED PNEUMONIA | BACTEREMIA | CARBAPENEMASE | PREVALENCE | PATHOGENS | CRITICAL CARE MEDICINE | Pseudomonas aeruginosa - isolation & purification | Humans | Middle Aged | Cross Infection - mortality | Male | Pseudomonas Infections - mortality | Hospital Mortality - trends | Anti-Bacterial Agents - therapeutic use | Pneumonia, Bacterial - mortality | Adult | Female | Retrospective Studies | Pseudomonas Infections - drug therapy | Pseudomonas Infections - diagnosis | Mortality - trends | Pneumonia, Bacterial - diagnosis | Pseudomonas aeruginosa - drug effects | Cross Infection - drug therapy | Internationality | Hospitalization - trends | Cross Infection - diagnosis | Pneumonia, Bacterial - drug therapy | Aged | Anti-Bacterial Agents - pharmacology | Drug Resistance, Multiple, Bacterial - drug effects | Medical research | Drug resistance in microorganisms | Pneumonia | Bacterial pneumonia | Mortality | Medicine, Experimental | Diabetes | Comparative analysis | France | Health aspects | Risk factors | Patient safety | Multidrug resistant organisms | Drug resistance | Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Zooanthroponotic transmission of drug-resistant pseudomonas aeruginosa, Brazil
by Fernandes, Miriam R and Sellera, Fábio P and Moura, Quézia and Carvalho, Marcelo P. N and Rosato, Paula N and Cerdeira, Louise and Lincopan, Nilton
Emerging Infectious Diseases, ISSN 1080-6040, 06/2018, Volume 24, Issue 6, pp. 1160 - 1162
We recovered VIM-2 carbapenemase-producing Pseudomonas aeruginosa isolates from an infected dog, its owner, and the domestic environment. Genomic investigation... 
ANIMALS | ACINETOBACTER-BAUMANNII | INFECTIOUS DISEASES | BETA-LACTAMASES | IMMUNOLOGY | KLEBSIELLA-PNEUMONIAE | Dog Diseases - epidemiology | Humans | Dog Diseases - microbiology | Drug Resistance, Bacterial | Pseudomonas aeruginosa - drug effects | Pseudomonas Infections - microbiology | Zoonoses | Microbial Sensitivity Tests | Pseudomonas Infections - transmission | Animals | beta-Lactamases - genetics | Pseudomonas Infections - epidemiology | Pseudomonas aeruginosa - genetics | Dogs | Anti-Bacterial Agents - pharmacology | Pseudomonas aeruginosa - classification | Brazil - epidemiology | Pseudomonas aeruginosa | Disease transmission | Drug resistance | Health aspects | reverse zoonosis | zooanthroponosis | Zooanthroponotic Transmission of Drug-Resistant | bacteria | antimicrobial resistance | nosocomial bacteria | household transmission | Brazil | domicile setting | metallo-β-lactamase | Research Letter
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Pseudomonas aeruginosa ventilator-associated pneumonia management
by Ramírez-Estrada, Sergio and Borgatta, Bárbara and Rello, Jordi
Infection and Drug Resistance, ISSN 1178-6973, 01/2016, Volume 9, pp. 7 - 18
Ventilator-associated pneumonia is the most common infection in intensive care unit patients associated with high morbidity rates and elevated economic costs;... 
Care-bundles | Multidrug-resistant | ICU | New-antibiotics | Adjunctive-therapies | INFECTIOUS DISEASES | RISK-FACTORS | ANTIMICROBIAL THERAPY | HOSPITAL-ACQUIRED PNEUMONIA | multidrug-resistant | IN-VITRO | COMPLICATED INTRAABDOMINAL INFECTIONS | CEFTAZIDIME-AVIBACTAM | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | adjunctive-therapies | MONOCLONAL-ANTIBODIES | CRITICALLY-ILL PATIENTS | new-antibiotics | care-bundles | SEVERE SEPSIS | Pathogens | Ventilators | Pneumonia | Immunoglobulins | Intensive care | Ventilator-associated pneumonia | Mortality | Cloning | Virulence | Infections | Management | Morbidity | Proteins | Intensive care units | Hospitals | Antibiotics | Chronic illnesses
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Risk Factors for Carbapenem-Resistant Pseudomonas aeruginosa, Zhejiang Province, China
by Hu, YY and Cao, JM and Yang, Q and Chen, S and Lv, HY and Zhou, HW and Wu, ZW and Zhang, R
EMERGING INFECTIOUS DISEASES, ISSN 1080-6040, 10/2019, Volume 25, Issue 10, pp. 1861 - 1867
Carbapenem-resistant Pseudomonas aeruginosa (CRPA) is a public health concern worldwide, but comprehensive analysis of risk factors for CRPA remains limited in... 
SURVEILLANCE | INFECTIOUS DISEASES | MECHANISMS | IMMUNOLOGY | NOSOCOMIAL INFECTIONS | Carbapenem | bacteria | antimicrobial resistance | China | Risk Factors for Carbapenem-Resistant | Pseudomonas aeruginosa | Research | Zhejiang Province, China | surveillance | risk factor | multidrug-resistant | risk factors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance
by Haidar, Ghady and Philips, Nathan J and Shields, Ryan K and Snyder, Daniel and Cheng, Shaoji and Potoski, Brian A and Doi, Yohei and Hao, Binghua and Press, Ellen G and Cooper, Vaughn S and Clancy, Cornelius J and Nguyen, M. Hong
Clinical Infectious Diseases, ISSN 1058-4838, 07/2017, Volume 65, Issue 1, pp. 110 - 120
Background. Data on the use of ceftolozane-tazobactam and emergence of ceftolozane-tazobactam resistance during multidrug resistant (MDR)-Pseudomonas... 
ceftolozane-tazobactam | MDR Pseudomonas | AmpC beta-lactamase | omega loop | resistance mechanisms | STRAINS | BETA-LACTAM RESISTANCE | AMPC | INFECTIOUS DISEASES | RISK-FACTORS | ACQUIRED PNEUMONIA | MICROBIOLOGY | IMMUNOLOGY | CARBAPENEM-RESISTANT | IMPACT | EFFLUX | CYSTIC-FIBROSIS PATIENTS | PATIENT OUTCOMES | Penicillanic Acid - pharmacology | Pseudomonas Infections - drug therapy | Humans | Middle Aged | Male | Pseudomonas aeruginosa - drug effects | Pseudomonas Infections - microbiology | Cephalosporins - therapeutic use | Young Adult | Anti-Bacterial Agents - therapeutic use | Genome, Bacterial - genetics | Pseudomonas Infections - epidemiology | Pseudomonas aeruginosa - genetics | Aged, 80 and over | Penicillanic Acid - therapeutic use | Adult | Female | Aged | Anti-Bacterial Agents - pharmacology | Retrospective Studies | Cephalosporins - pharmacology | Drug Resistance, Multiple, Bacterial - drug effects | Pennsylvania - epidemiology | Penicillanic Acid - analogs & derivatives | Pseudomonas aeruginosa infections | Care and treatment | Usage | Drug-resistant Streptococcus pneumoniae | Research | Tazobactam | and Commentaries
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Genomics and susceptibility profiles of extensively drug-resistant pseudomonas aeruginosa isolates from Spain
by Del Barrio-Tofiño, Ester and López-Causapé, Carla and Cabot, Gabriel and Rivera, Alba and Benito, Natividad and Segura, Concepción and Montero, María Milagro and Sorlí, Luisa and Tubau, Fe and Gómez-Zorrilla, Silvia and Tormo, Nuria and Durá-Navarro, Raquel and Viedma, Esther and Resino-Foz, Elena and Fernández-Martínez, Marta and González-Rico, Claudia and Alejo-Cancho, Izaskun and Martínez, Jose Antonio and Labayru-Echverria, Cristina and Dueñas, Carlos and Ayestarán, Ignacio and Zamorano, Laura and Martinez-Martinez, Luis and Horcajada, Juan Pablo and Oliver, Antonio
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 11/2017, Volume 61, Issue 11
This study assessed the molecular epidemiology, resistance mechanisms, and susceptibility profiles of a collection of 150 extensively drug-resistant (XDR)... 
BETA-LACTAM RESISTANCE | CONVERGENT EVOLUTION | AMINOGLYCOSIDE RESISTANCE | whole-genome sequencing | CXA-101 FR264205 | extensively drug resistant | MICROBIOLOGY | POLYMYXIN RESISTANCE | ANTIMICROBIAL RESISTANCE | Pseudomonas aeruginosa | PHARMACOLOGY & PHARMACY | CEFTOLOZANE-TAZOBACTAM | MUTATIONS | high-risk clones | FIELD GEL-ELECTROPHORESIS | CARBAPENEM RESISTANCE
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of ampc
by Cabot, Gabriel and Bruchmann, Sebastian and Mulet, Xavier and Zamorano, Laura and Moyá, Bartolomé and Juan, Carlos and Haussler, Susanne and Olivera, Antonio
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 2014, Volume 58, Issue 6, pp. 3091 - 3099
We compared the dynamics and mechanisms of resistance development to ceftazidime, meropenem, ciprofloxacin, and ceftolozane-tazobactam in wild-type (PAO1) and... 
BETA-LACTAM RESISTANCE | HIGH-RISK CLONES | CEPHALOSPORIN CXA-101 | GENETIC-DETERMINANTS | CXA-101 FR264205 | CLINICAL STRAINS | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | MECHANISMS | DRUG-RESISTANCE | CARBAPENEM-RESISTANT | BLOOD-STREAM INFECTIONS | Penicillanic Acid - pharmacology | Ceftazidime - pharmacology | Bacterial Proteins - genetics | Pseudomonas aeruginosa - drug effects | Thienamycins - pharmacology | Pseudomonas Infections - microbiology | Imipenem - pharmacology | Microbial Sensitivity Tests | Piperacillin - pharmacology | beta-Lactamases - genetics | Pseudomonas aeruginosa - genetics | Bacterial Proteins - metabolism | Anti-Bacterial Agents - pharmacology | Mutation | beta-Lactamases - metabolism | Cephalosporins - pharmacology | Penicillanic Acid - analogs & derivatives | Mechanisms of Resistance
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Inhibition and destruction of Pseudomonas aeruginosa biofilms by antibiotics and antimicrobial peptides
by Dosler, S and Karaaslan, E
PEPTIDES, ISSN 0196-9781, 12/2014, Volume 62, pp. 32 - 37
Pseudomonas aeruginosa is one of the major nosocomial pathogen that can causes a wide variety of acute and chronic infections P. aeruginosa is a dreaded... 
LL-37 | Destruction | Antimicrobial cationic peptides | EFFICACY | BIOCHEMISTRY & MOLECULAR BIOLOGY | P. aeniginosa | MECHANISMS | RESISTANT STAPHYLOCOCCUS-AUREUS | CATIONIC PEPTIDES | COMBINATION | HOST-DEFENSE PEPTIDES | ACINETOBACTER-BAUMANNII | Time kill curve | Biofilm | PHARMACOLOGY & PHARMACY | THERAPEUTIC STRATEGIES | Inhibition | CYSTIC-FIBROSIS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients
by Tumbarello, Mario and De Pascale, Gennaro and Trecarichi, Enrico Maria and Spanu, Teresa and Antonicelli, Federica and Maviglia, Riccardo and Pennisi, Mariano Alberto and Bello, Giuseppe and Antonelli, Massimo
Intensive Care Medicine, ISSN 0342-4642, 4/2013, Volume 39, Issue 4, pp. 682 - 692
Our aim was to identify the clinical profile of intensive care unit (ICU) patients with Pseudomonas aeruginosa (PA) pneumonia and the impact on ICU mortality... 
Pediatrics | Pain Medicine | Pneumonia | Ventilator-associated pneumonia | Emergency Medicine | Pneumology/Respiratory System | Medicine & Public Health | Multidrug resistance | Intensive / Critical Care Medicine | Anesthesiology | P. aeruginosa | MORTALITY | RESPIRATORY-TRACT | BLOOD-STREAM INFECTION | RISK-FACTORS | RESISTANT STAPHYLOCOCCUS-AUREUS | ANTIMICROBIAL RESISTANCE | ANTIBIOTIC-THERAPY | IMPACT | NOSOCOMIAL PNEUMONIA | CRITICAL CARE MEDICINE | Pseudomonas aeruginosa - isolation & purification | Humans | Middle Aged | Male | Pseudomonas Infections - mortality | Anti-Bacterial Agents - therapeutic use | Rome | Pneumonia, Bacterial - mortality | Aged, 80 and over | Adult | Female | Retrospective Studies | Length of Stay | Intensive Care Units | Pneumonia, Bacterial - microbiology | Hospital Mortality | Pseudomonas Infections - drug therapy | Logistic Models | Treatment Outcome | Pseudomonas aeruginosa - drug effects | Cross Infection - drug therapy | Cross Infection - microbiology | Respiration, Artificial - statistics & numerical data | Pneumonia, Bacterial - drug therapy | Aged | Drug Resistance, Multiple, Bacterial - drug effects | Patient outcomes | Bacterial pneumonia | Pseudomonas aeruginosa | Research | Drug therapy | Health aspects | Artificial respiration
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights